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OBJECTIVES We compared the ability of inhaled nitric oxide (NO), oxygen (O2) and nitric oxide in oxygen
(NO1O2) to identify reactive pulmonary vasculature in pulmonary hypertensive patients
during acute vasodilator testing at cardiac catheterization.
BACKGROUND In patients with pulmonary hypertension, decisions regarding suitability for corrective
surgery, transplantation and assessment of long-term prognosis are based on results obtained
during acute pulmonary vasodilator testing.
METHODS In group 1, 46 patients had hemodynamic measurements in room air (RA), 100% O2, return
to RA and NO (80 parts per million [ppm] in RA). In group 2, 25 additional patients were
studied in RA, 100% O2 and 80 ppm NO in oxygen (NO1O2).
RESULTS In group 1, O2 decreased pulmonary vascular resistance (PVR) (mean 6 SEM) from 17.2 6
2.1 Uzm2 to 11.1 6 1.5 Uzm2 (p , 0.05). Nitric oxide caused a comparable decrease from
17.8 6 2.2 Uzm2 to 11.7 6 1.7 Uzm2 (p , 0.05). In group 2, PVR decreased from 20.1 6
2.6 Uzm2 to 14.3 6 1.9 Uzm2 in O2 (p , 0.05) and further to 10.5 6 1.7 Uzm
2 in NO1O2
(p , 0.05). A response of 20% or more reduction in PVR was seen in 22/25 patients with
NO1O2 compared with 16/25 in O2 alone (p 5 0.01).
CONCLUSIONS Inhaled NO and O2 produced a similar degree of selective pulmonary vasodilation. Our data
suggest that combination testing with NO1O2 provides additional pulmonary vasodilation in
patients with a reactive pulmonary vascular bed in a selective, safe and expeditious fashion
during cardiac catheterization. The combination of NO1O2 identifies patients with
significant pulmonary vasoreactivity who might not be recognized if O2 or NO were used
separately. (J Am Coll Cardiol 1999;33:813–9) © 1999 by the American College of
Cardiology
Elevated pulmonary vascular resistance (PVR) complicates
the evaluation, clinical course and outcome of patients with
congenital heart disease or end-stage pulmonary disease. It
is a crucial factor in determining the timing or type of
intervention, and has been invoked as the primary determi-
nant of mortality in many lesions (1,2). Opinion varies on
what resistance must be achieved with vasodilator testing to
insure safe operability for children with congenital heart
disease. An increased or fixed elevation in PVR may deny
patients the chance of corrective surgery, leaving them
susceptible to the development of progressive obliterative
pulmonary vascular disease and reduced life expectancy
(3,4). Demonstration of pulmonary vasoreactivity in pa-
tients with end-stage pulmonary disease may differentiate
patients who would benefit from long-term medical therapy
(5,6) from those with high, fixed resistance who should be
more urgently considered for lung transplantation (3). Safe
and expeditious demonstration of maximal pulmonary va-
sodilation in patients with a reactive pulmonary bed is
therefore an important objective.
Many vasodilators have been utilized for diagnostic test-
ing during cardiac catheterization. Systemic vasodilators
with their attendant risks of hypotension and increased
intrapulmonary shunt may be hazardous (7), especially in
patients with ventricular outflow tract obstruction. Breath-
ing oxygen (O2) remains a standard means of pulmonary
vasodilator testing in pediatric cardiac catheterization labo-
ratories (8,9). However, failure to respond to acute treat-
ment with O2 has been reported in some patients who did
indeed have reactive pulmonary vasculature (3,10).
Inhaled nitric oxide (NO) is a selective pulmonary vaso-
dilator with minimal systemic effects and does not increase
intrapulmonary shunting. It can be administered easily with
O2 or room air (RA) during cardiac catheterization by either
ventilator or mask. The purpose of this study was to
compare the ability of NO and O2 to identify patients with
a reactive pulmonary vascular bed during cardiac catheter-
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ization. We further compared the hemodynamic effects of
breathing nitric oxide in oxygen (NO1O2) to breathing O2
alone during acute vasodilator testing.
METHODS
We enrolled patients between January 1992 and December
1996 who had mean pulmonary artery pressure
$30 mm Hg, PVR .3 Uzm2, and were determined during
catheterization to require vasodilator testing. We included
for analysis 71 patients who had complete hemodynamic
measurements to allow calculation of vascular resistances.
Study groups. The first 46 patients (group 1) were studied
under the following four study conditions: A) in RA; B)
after breathing 100% O2 for 15 min; C) after another
15 min in RA, and D) after 15 min breathing NO at 80
parts per million (ppm) in 23% O2 (NO1RA). As NO is
titrated into a delivery circuit, the delivered fraction of
inspired O2 (FiO2) is decreased. Therefore a small amount
of supplemental O2 (23%) was added to NO to avoid
administration of a hypoxic gas mixture. The patients in group
1 had a median age of 6.5 years, range 4 months to 59 years.
Twenty-five additional patients (group 2) were studied in
the following three conditions: A) in RA; B) after breathing
100% O2 for 15 min, and C) after 15 min of inhaling 80
ppm NO in 91% O2. This was the maximal FiO2 attainable
after dilution with 80 ppm of NO. Patients in group 2 had
a median age of 3.5 years, range 5 months to 69 years.
The patients in each group represented a broad spectrum
of diagnoses characteristic of a high volume pediatric cardiac
catheterization laboratory. Most had unrepaired or previ-
ously palliated congenital heart disease, although some had
end-stage pulmonary disease (Tables 1 and 2). Four of 46
patients in group 1 and three of 25 patients in group 2 were
mechanically ventilated. The remainder in each group were
breathing spontaneously. Sedation was given according to a
routine, which included intravenous morphine and midazo-
lam. Partial pressure of carbon dioxide (PCO2) was normal
throughout the study in both groups.
Hemodynamic assessment. Hemodynamic measurements
included left atrial, right atrial, pulmonary and systemic
arterial pressures during each of the conditions described
above. Cardiac output was measured by thermodilution in
patients without an intracardiac shunt. In those with shunts,
O2 consumption was measured (Waters Inc., model
MM20, Rochester, Minnesota), and systemic and pulmo-
nary blood flows were calculated using the Fick equation
with inclusion of dissolved O2. Errors related to sampling
site variances were minimized by ensuring that, for each
patient, venous samples were collected at the same site
during each of the study conditions.
Delivery and monitoring of NO. Detailed descriptions of
the technical aspects of our delivery of NO in both venti-
lated and spontaneously breathing patients have been pub-
lished previously (11,12). We used NO gas (Scott Specialty
Gases, Plumsteadville, Pennsylvania or BOC Gases, Mur-
ray Hill, New Jersey) of medical grade quality, which
Table 1. Diagnoses of Patients in Group 1 (n 5 46)
Unrepaired Heart Disease
(n 5 26) n
Repaired Heart Disease
(n 5 14) n
Lung Pathology
(n 5 6) n
VSD 5(1) Complex single ventricle postpalliation 4(1) Pulmonary emboli 3(2)
CAVC 5 TGA post Senning 3(1) Restrictive lung disease (lupus) 1
Shone’s syndrome 5 TGA/VSD post PAB 2 Primary pulmonary hypertension 1
PDA 2 TGA post Mustard 1 Cystic fibrosis 1
Cardiomyopathy 2 TGA post ASO 1(1)
VSD with PDA 1 CAVC repair 1
Truncus arteriosus 1 TOF/PA full repair 1
ASD primum 1 ASD secundum 1
ASD secundum with PDA 1
Supracardiac TAPVC 1
ASD secundum 1
TGA/VSD 1
In parentheses is the number of patients who did not respond to either oxygen or nitric oxide.
ASD 5 atrial septal defect; ASO 5 arterial switch operation; CAVC 5 complete atrioventricular canal; PAB 5 pulmonary artery band; PDA 5 patent ductus arteriosus;
Shone’s syndrome 5 multiple left-sided obstructive lesions; TAPVC 5 total anomalous pulmonary venous connection; TGA 5 transposition of the great arteries; TOF/PA 5
tetralogy of Fallot with pulmonary atresia; VSD 5 ventricular septal defect.
Abbreviations and Acronyms
FiO2 5 fraction of inspired oxygen
NO 5 nitric oxide
NO2 5 nitrogen dioxide
O2 5 oxygen
PaCO2 5 partial pressure of carbon dioxide, arterial
PCO2 5 partial pressure of carbon dioxide
ppm 5 parts per million
PVR 5 pulmonary vascular resistance
RA 5 room air
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conformed to Food and Drug Administration standards. In
the spontaneously breathing individuals NO was delivered
using the titration technique from source tanks with an
800-ppm concentration. Flow rates greater than the pa-
tients’ minute volumes were delivered through a one-way
inspiratory valve to a face mask. The expired gases were
scavenged using a reservoir bag and regulated wall suction.
In the seven patients who were mechanically ventilated,
ventilator settings were kept constant throughout the study.
Nitric oxide, nitrogen dioxide (NO2) and FiO2 were con-
tinuously monitored from a sampling port at the airway
(Thermoenvironmental Instruments Chemiluminescence
model 42H, Franklin, Massachusetts or NOxBOX Electro-
chemical Inhaled NO Therapy Monitor, Bedfont Scientific
USA, Medford, New Jersey). Peak measured NO2 concentra-
tions were recorded in all patients during delivery of the drug.
Because there were no reports of methemoglobinemia during
15-min diagnostic trials of NO at 80 ppm (11), we eventually
ceased to routinely measure methemoglobin levels during brief
inhalations. Therefore, methemoglobin levels were obtained by
cooximetry (CIBA-Corning model 2500, Medfield, Massa-
chusetts) after 15 min in the first 22 of 46 patients in group 1
and not thereafter. Written informed consent was obtained
from the patients or their parents under a protocol approved by
the Clinical Investigation Committee of Children’s Hospital
and submitted to the Food and Drug Administration.
Statistical analysis and calculations. Results are presented
as mean values 6 SEM. Vascular resistances were calculated
using standard equations and were expressed in Wood units
corrected for body surface area (Uzm2). Groups 1 and 2 were
analyzed separately with patients in each group acting as
their own controls. Repeated measures analysis of variance
was used to look for differences in the measurements over
the four study conditions in group 1 and the three condi-
tions in group 2. If differences were found, then the
Bonferroni multiple comparisons procedure was used to
determine where differences existed. A p value ,0.05 was
considered significant.
RESULTS
Group 1: comparison of RA, O2, RA and NO1RA.
Pulmonary vascular resistance differed across the four con-
ditions, (p , 0.0001) (Table 3). Oxygen decreased PVR
from 17.2 6 2.1 Uzm2 to 11.1 6 1.5 Uzm2 (p , 0.05).
Administration of inhaled NO at 80 ppm in RA caused a
comparable decrease from 17.8 6 2.2 Uzm2 to 11.7 6
1.7 Uzm2 (p , 0.05) (Fig. 1). Comparison of the mean
percentage decreases from RA to O2 (36.9 6 3.3%) and RA
to NO1RA (35.1 6 3.5%) revealed no difference by paired
t test. Changes in pulmonary artery pressures may not reflect
pulmonary vasodilation, because there were patients with
intracardiac shunts. Nevertheless, the mean pulmonary ar-
tery pressure was significantly lower in both O2 and
NO1RA compared with RA despite increases in pulmo-
nary blood flow in 21 of 23 patients with intracardiac shunts
during treatment.
Mean systemic arterial pressure, systemic vascular resis-
tance, right atrial pressure, left atrial pressure, heart rate, pH
and PCO2 did not change with administration of O2 or NO.
Arterial PCO2 (PaO2) increased from 66 6 3 mm Hg in RA
to 278 6 23 mm Hg with 100% O2; however, there was no
significant difference in PaO2 between RA and NO1RA
(68 6 4 vs. 73 6 4 mm Hg).
Using a reduction in PVR of 20% or more as a marker for
responsiveness, we compared individual patient results to
O2 and NO1RA (Fig. 2). Oxygen caused a positive
response in 36/46 patients. Of the 10 nonresponders, four
responded with a 20% or more decrease to NO. Nitric oxide
in RA caused a positive response in 32/46. Of the 14
nonresponders to NO1RA, eight responded to O2. Six
patients did not respond to either vasodilator (Table 1).
The peak NO2 level was recorded in all 46 patients and
was 1.3 6 0.2 ppm. Methemoglobin measured at the
conclusion of the 15-min period of NO inhalation in 22/46
patients was 0.8 6 0.1%.
Group 2: comparison of RA, O2 and NO1O2. Pulmo-
nary vascular resistance differed across the three conditions
(p , 0.0001) (Table 4). Pulmonary vascular resistance
Table 2. Diagnoses of Patients in Group 2 (n 5 25)
Unrepaired Heart Disease
(n 5 19) n
Repaired Heart Disease
(n 5 3) n
Lung Pathology
(n 5 3) n
VSD 5 PDA 1 COPD 1(1)
CAVC 1 TAPVC with PV stenosis 1(1) Primary pulmonary hypertension 1
Shone’s syndrome 3 TOF/PA 1 Pulmonary emboli 1
PDA 1
ASD secundum 4(1)
VSD with mitral stenosis 2
VSD with coarctation 1
ASD primum 1
Cardiomyopathy 1
In parentheses is the number of patients who did not respond to either oxygen or nitric oxide in oxygen.
COPD 5 chronic obstructive pulmonary disease; PV 5 pulmonary vein; other abbreviations as in Table 1.
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decreased from 20.1 6 2.6 Uzm2 in RA to 14.3 6 1.9 Uzm2
in O2 and further to 10.5 6 1.7 Uzm
2 in NO1O2 (Fig. 3).
Pulmonary vascular resistance was significantly lower in O2
compared to RA (p , 0.05). The PVR with combination
therapy was statistically lower than that measured in air or in
O2 (p , 0.05 for both). Oxygen caused a reduction in PVR
from baseline of 20% or more in 16 of 25 patients. Of the
remaining nine patients, six responded with a 20% or more
decrease when inhaling NO1O2. Three patients did not
have a positive response to either O2 or the combination of
O2 and NO (see Table 2). Using the McNemar’s test, if
responsiveness differed between the two treatments, patients
were more likely to respond to NO1O2 than to O2 alone
(p 5 0.01). Ten of the 25 patients underwent complete
surgical repair of their cardiac defects within 1 month of
their catheterization. Those 10 patients had a baseline PVR
in RA of 12.9 6 1.9 Uzm2 that decreased to 7.1 6 1.9 Uzm2
in O2 and to 4.1 6 1.9 Uzm
2 in NO1O2. Each patient
undergoing surgical repair had a baseline PVR in RA
.6 Uzm2. Five of 10 had PVR .6 Uzm2 in O2, but only one
had PVR .6 Uzm2 in NO1O2. All 10 patients survived
and were discharged home on median postoperative day 5.5,
range 4 to 29.
Mean pulmonary artery pressure decreased from 63.4 6
3.7 mm Hg in RA to 57.7 6 3.5 mm Hg in O2 to 50.6 6
3.5 mm Hg in NO1O2. This occurred despite an increase
in pulmonary blood flow in 13 of 15 patients with shunts.
The pulmonary artery pressure with NO1O2 was signifi-
cantly lower than that measured in air or in O2 (p , 0.05 for
both). There was no difference between left atrial pressure in
RA and in O2. Left atrial pressure was significantly higher
in NO1O2 (15.5 6 1.3 mm Hg) than in RA (13.1 6
1.1 mm Hg) or O2 (12.7 6 1.0 mm Hg).
Mean systemic blood pressure increased over the three
study conditions, from 76.8 6 2.9 mm Hg in RA to 80.6 6
2.5 mm Hg in O2 to 83.4 6 2.6 mm Hg in NO1O2. Blood
pressure was significantly higher in NO1O2 than in RA,
but not statistically different from blood pressure in O2.
Cardiac index, systemic vascular resistance, right atrial
pressure, heart rate, pH and PCO2 did not change. Arterial
Figure 1. Pulmonary vascular resistance (PVR) (mean 6 SE)
differed across the four study conditions in group 1 (p , 0.0001);
PVR was lower in oxygen (O2) compared with room air (RA) (*)
and was lower in nitric oxide in RA (NO1RA) compared with RA
(†) (p , 0.05 for both).
Figure 2. Individual patients’ percentage change in PVR with O2
is plotted against percentage change in PVR with NO1RA. Using
a 20% decrease in PVR as a marker for responsiveness, some
patients responded to one drug only. Neither O2 nor NO1RA
identified all patients with pulmonary vasoreactivity. Abbreviations
as in Figure 1.
Table 3. Hemodynamic Data for Group 1
Variable
(mean 6 SEM) A: RA B: Oxygen C: RA D: NO1RA
ANOVA
p Value
PVR (Uzm2) 17.2 6 2.1 11.1 6 1.5 17.8 6 2.2 11.7 6 1.7 , 0.0001*†
mPAp (mm Hg) 62.7 6 3.3 54.9 6 3.1 60.9 6 3.4 51.2 6 3.0 , 0.0001*†
LAp (mm Hg) 13.7 6 0.8 14.6 6 1.0 14.0 6 0.9 14.9 6 1.1 0.05
CI (liters/min/m2) 3.6 6 0.3 3.2 6 0.2 3.5 6 0.2 3.3 6 0.2 0.19
RAp (mm Hg) 9.0 6 0.5 9.1 6 0.5 8.8 6 0.5 8.4 6 0.5 0.08
MAP (mm Hg) 79.2 6 2.3 81.0 6 2.3 79.5 6 2.6 79.4 6 2.6 0.55
SVR (Uzm2) 24.2 6 1.8 25.7 6 1.6 24.2 6 1.8 24.8 6 1.7 0.33
pH 7.36 6 0.01 7.36 6 0.01 7.35 6 0.01 7.35 6 0.01 0.43
PCO2 41.6 6 1.1 41.2 6 1.0 41.8 6 1.1 43.0 6 1.2 0.07
PO2 65.6 6 2.7 277.6 6 23.2 68.1 6 3.6 73.5 6 3.5 , 0.0001*
Heart rate 108 6 4 107 6 4 104 6 5 105 6 5 0.24
*Variable in oxygen (B) is different than in room air (A) (p , 0.05). †Variable in nitric oxide (D) is different than in room air
(C) (p , 0.05).
ANOVA 5 analysis of variance; CI 5 cardiac index; LAp 5 left atrial pressure; MAP 5 mean arterial blood pressure;
mPAp 5 mean pulmonary artery pressure; PCO2 5 partial pressure of carbon dioxide; PO2 5 partial pressure of oxygen; PVR 5
pulmonary vascular resistance; RA 5 room air; RAp 5 right atrial pressure; SVR 5 systemic vascular resistance.
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partial pressure of O2 was significantly higher both in O2
and in NO1O2 as compared with RA. Arterial partial
pressure of O2 was not different in NO1O2 compared with
O2 (302.8 6 27.9 vs. 277.6 6 30.4 mm Hg). The peak NO2
level during NO delivery was 2.3 6 0.3 ppm.
DISCUSSION
We compared the inhaled vasodilators O2 and NO in 71
patients during acute vasodilator testing at cardiac catheter-
ization. In 46 patients, 100% O2 and inhaled NO at 80 ppm
in air produced comparable and selective decreases in mean
pulmonary artery pressure and PVR. However, O2 or NO
used separately failed to identify all patients with a signifi-
cant capacity for pulmonary vasodilation. The combination
of NO (80 ppm) with 91% O2 in an additional group of 25
patients produced significantly more pulmonary vasorelax-
ation compared with O2 used alone. In 22/25 patients there
was a positive pulmonary vasodilator response during com-
bination therapy compared to only 16/25 when breathing
O2 alone. None of the 71 patients studied showed any
evidence of toxicity from either drug during the brief period
of this diagnostic trial. Our data suggest that combination
testing with NO in O2 provides additional pulmonary
vasodilation, can be safely and accurately delivered to
patients during diagnostic cardiac catheterization and can
rapidly identify patients with pulmonary vasoreactivity. The
combination of agents appears to identify patients with
significant pulmonary vasoreactivity who might not be
recognized if O2 or NO were used separately.
Importance of vasodilator testing. The precise stage when
pulmonary vascular disease has progressed to a point where
surgical repair of congenital heart lesions cannot be safely
performed is unknown. Morphologic criteria (2) and pul-
monary hemodynamics (13) are useful, but imprecise. Pul-
monary vascular resistance calculated to be more than 6 to
8 Uzm2 has been shown to be associated with poor operative
outcome regardless of lung histology (1,4,14). In contrast,
patients who respond to vasodilators with a PVR less than
6 to 8 Uzm2 do well postoperatively (13). Demonstration of
a reactive pulmonary bed in patients being evaluated for
transplantation has enabled patients to be offered a single
organ heart instead of heart–lung block with successful
results (15). Patients with elevated resistance but reactive
pulmonary vasculature may need more intensive postoper-
ative care and presumably would be excellent candidates for
NO therapy in the postoperative period should pulmonary
hypertension emerge. Response to acute vasodilator testing
in patients with primary pulmonary hypertension is an
important marker for survival (3) and may identify patients
who would benefit from chronic medical therapy (5,6).
Comparison with other studies. Prior research in children
with pulmonary hypertension has shown that O2 failed to
unmask all reversible pulmonary vasoconstriction (3,10).
Prostacyclin administration in patients with pulmonary
hypertension breathing O2 caused further pulmonary vaso-
dilation. However, prostacyclin can cause systemic side
effects including tachycardia and hypotension (16). Previous
studies of vasoreactivity in children during cardiac catheter-
ization found variable responsiveness to NO that seemed to
Table 4. Hemodynamic Data for Group 2
Variable
(mean 6 SEM) A: RA B: Oxygen C: NO1O2
ANOVA
p Value
PVR (Uzm2) 20.1 6 2.6 14.3 6 1.9 10.5 6 1.7 , 0.0001*†‡
mPAp (mm Hg) 63.4 6 3.7 57.7 6 3.5 50.6 6 3.5 0.0002†‡
LAp (mm Hg) 13.1 6 1.1 12.7 6 1.0 15.5 6 1.3 0.002†‡
CI (liter/min/m2) 3.1 6 0.3 3.2 6 0.3 3.2 6 0.3 0.93
RAp (mm Hg) 8.0 6 0.7 8.3 6 0.8 8.4 6 0.7 0.78
MAP (mm Hg) 76.8 6 2.9 80.6 6 2.5 83.4 6 2.6 0.004‡
SVR (Uzm2) 26.8 6 2.7 28.1 6 2.6 29.8 6 3.0 0.34
pH 7.38 6 0.01 7.36 6 0.01 7.36 6 0.01 0.08
PCO2 38.8 6 1.2 39.7 6 1.5 40.5 6 1.7 0.27
PO2 67.3 6 3.9 277.6 6 30.4 302.8 6 27.9 , 0.0001*‡
Heart rate 108 6 4 107 6 4 105 6 5 0.58
*Variable in oxygen (B) is different than in room air (A) (p , 0.05). †Variable in NO1O2 (C) is different than in oxygen (B)
(p , 0.05). ‡Variable in NO1O2 (C) is different than in room air (A) (p , 0.05). Abbreviations as in Table 3.
Figure 3. Pulmonary vascular resistance (mean 6 SE) differed
across the three study conditions in group 2 (p , 0.0001); PVR
was lower in O2 compared with RA (*) and was lower in NO1O2
compared with RA (*) and O2 (†) (p , 0.05 for all comparisons).
Abbreviations as in Figure 1.
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parallel the progression of established vascular disease (17).
Studies examining the efficacy of NO in O2, including
recent work by Allman and colleagues, have suggested differ-
ences between the responses to NO, O2 and/or the combina-
tion of agents (18–20). Each prior study, however, has had
insufficient power to establish a significant difference in PVR.
Nitric oxide causes vasorelaxation through a cyclic
guanosine monophosphate–mediated pathway. The mech-
anism of vasorelaxation caused by O2 is not clearly known
(21). The fact that some patients responded to one agent
with significant vasodilation but not the other, and that the
majority of patients experienced increased vasodilation with
combination therapy compared with O2 alone, suggests that
the mechanisms may not be identical.
Potential toxicities. The major recognized toxicities asso-
ciated with inhaling NO are cytotoxic effects in the lung due
to exposure to excess NO2 and methemoglobinemia due to
the intravascular binding to hemoglobin. Nitrogen dioxide
will develop in delivery systems at a rate that is proportional
to NO and O2 concentrations and contact times between
the two gases. When NO was delivered with maximal
amounts of O2 in this study, NO2 levels averaged 2.3 6
0.3 ppm, below the accepted environmental exposure level
of 5 ppm (22). Nitrogen dioxide should be continuously
monitored, especially in patients mechanically ventilated
with circuits that do not use continuous gas flows. If
patients receive prolonged treatment with NO in high
concentrations of O2, we recommend reduction in the NO
dose to diminish potential dose-related toxicity. There have
been no reports of clinically significant methemoglobinemia
during brief exposure to NO at doses as high as 80 ppm.
Methemoglobin measured at the conclusion of the 15-min
period of NO inhalation in 22/46 patients was 0.8 6 0.1%.
This along with previously published results (11) supports
the contention that routine measurement of methemoglobin
may be unnecessary during brief diagnostic trials of NO.
It is notable that the combination of NO in O2 resulted
in an increase in left atrial pressure compared with RA or O2
alone. Reports have suggested that O2 (23) or NO (24) may
have deleterious effects to patients with heart failure. In this
study no patient demonstrated clinically important pulmo-
nary edema, hemodynamically significant systemic vasocon-
striction or decreased cardiac index during the brief admin-
istration of O2 or NO in O2. Nevertheless, we believe that
NO, especially when used with O2, should be carefully
monitored in patients with elevated left atrial pressures due
to the potential induction of pulmonary edema.
Study limitations. The patient population studied was
quite heterogeneous. However, this accurately reflects the
typical spectrum of patients presenting for vasodilator test-
ing during cardiac catheterization. Subgroup analysis of
patients with congenital heart disease showed no differences
in response compared to the group as a whole. Patients with
lung pathology analyzed separately showed similar results,
but numbers were too small to form conclusions. Subgroup
analysis of patients with left to right shunts did not reveal
any difference in response compared to those without
shunts. The definition of responder and nonresponder is
arbitrary, but a 20% change is often used in drug testing as
a marker of responsiveness. There was no apparent predic-
tive marker in patients who responded to one agent but not
the other. It may be that repeated exposure to O2 or NO
would minimize differences between responders and nonre-
sponders. Nonetheless, a single exposure to a drug is the
common catheterization protocol. Limited information ex-
ists concerning optimal dosing of NO, with some investi-
gators showing maximal vasodilation at doses as low as
2 ppm (19), and others demonstrating a dose–response
relationship up to 80 ppm in a similar population (18). This
study was designed as a brief diagnostic trial in a catheter-
ization laboratory to determine the most effective and
inclusive method of identifying patients with pulmonary
vasoreactivity. Accordingly, 80 ppm was used during this
brief testing with the appreciation that, if delivered for
prolonged periods, it may be associated with dose-related
increased toxicity. This study was not designed to demon-
strate differences in long-term patient outcomes or clinical
value of vasodilator testing. Maximal vasodilatory capacity
may be of limited clinical value in some patients. Neverthe-
less, as a result of information acquired during combination
therapy, some patients were offered surgery who did not
respond to NO or O2 alone; all patients survived.
Summary. Individually, NO and O2 produced significant
and comparable selective pulmonary vasodilation in a het-
erogeneous group of patients presenting to cardiac cathe-
terization for pulmonary vasodilator testing. However, nei-
ther agent used separately identified all patients with the
capacity to relax their pulmonary vascular bed. The combi-
nation of NO1O2 caused significantly greater pulmonary
vasodilation compared to O2 and identified patients who
had pulmonary vasoreactivity that was not appreciated
during O2 breathing alone. This study suggests that com-
bination testing with NO1O2 provides additional pulmo-
nary vasodilation in patients with a reactive pulmonary
vascular bed in a specific, safe and expeditious fashion
during cardiac catheterization. Nitric oxide in O2 distin-
guishes patients with significant pulmonary vasoreactivity
who might not be identified using either agent separately.
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